Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration

Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration

Current treatments for age-related neovascular macular degeneration (nAMD) suffer from limited efficacy. Here, Zhao et al. show that pharmacological inhibition or genetic deletion of the mineralocorticoid receptor (MR) limits choroidal neovascularisation in rodents, and show in a pilot clinical stud...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Min Zhao, Irmela Mantel, Emmanuelle Gelize, Xinxin Li, Xiaoyue Xie, Alejandro Arboleda, Marie Seminel, Rinath Levy-Boukris, Marilyn Dernigoghossian, Andrea Prunotto, Charlotte Andrieu-Soler, Carlo Rivolta, Jérémie Canonica, Marie-Christine Naud, Sebastian Lechner, Nicolette Farman, Irene Bravo-Osuna, Rocio Herrero-Vanrell, Frederic Jaisser, Francine Behar-Cohen
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/38bef37aaba649d6a6734776e59801e9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Current treatments for age-related neovascular macular degeneration (nAMD) suffer from limited efficacy. Here, Zhao et al. show that pharmacological inhibition or genetic deletion of the mineralocorticoid receptor (MR) limits choroidal neovascularisation in rodents, and show in a pilot clinical study that targeting the MR pathway may provide clinical benefits in nAMD patiens.

Ejemplares similares